Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES

Subclass of:

530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
530380000 Blood proteins or globulins, e.g., proteoglycans, platelet factor 4, thyroglobulin, thyroxine, etc. 949
530412000 Separation or purification 162
530402000 Chemical modification or the reaction product thereof, e.g., covalent attachment or coupling, etc. 123
530353000 Scleroproteins, e.g., fibroin, elastin, silk, etc. 83
530370000 Plant proteins, e.g., derived from legumes, algae or lichens, etc. 80
530395000 Glycoprotein, e.g., mucins, proteoglycans, etc. 70
530351000 Lymphokines, e.g., interferons, interlukins, etc. 63
530362000 Albumin 45
530399000 Hormones, e.g., prolactin, thymosin, growth factors, etc. 41
530400000 Metal containing, e.g., chromoproteins, ferritin, ferredoxins, etc. 12
530358000 Nucleoproteins, e.g., chromatin, chromosomal proteins, histones, protamines, salmine, etc. 11
530359000 Lipoproteins, e.g., egg yolk proteins, cylomicrons, etc. 9
530352000 Phosphoproteins, e.g., phosvitin, vitellogenin, etc. 2
20120142897PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY - Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.06-07-2012
20100331524IMMUNOMODULATORY PROTEIN AND USEFUL EMBODIMENTS THEREOF - The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.12-30-2010
Entries
DocumentTitleDate
20110207913Induction of Gene Expression Using a High Concentration Sugar Mixture - Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.08-25-2011
20120172576METHOD AND MARKER FOR SIMPLE TRANSFORMATION AND SELECTION OF RECOMBINANT PROTISTS - The present invention concerns a method for production of genetically modified (recombinant) protists without using negative selection markers, in which an auxotrophic mutant of the protist is produced, this mutant is then transformed with recombinant DNA containing at least one gene for complementation of the corresponding auxotrophy, and the resulting recombinant protist is finally selected on a minimal medium that makes possible growth of only the correspondingly complemented protist. The present invention also concerns an efficient method for production of proteins by protists so modified, in which the gene for the protein being produced is coupled to the marker gene.07-05-2012
20120184713Compositions and Methods for Modulation of Bone Density and Biomineralization - Compositions and methods for modulating FAM20C kinase action and identifying therapeutic agents for the same are disclosed.07-19-2012
20120184712HOMOGENOUS POPULATIONS OF MOLECULES - The invention provides populations of molecules that are prepared as, or treated to become, homogeneous for one or more molecular characteristics. In an aspect, the invention relates to molecular weight standards that may be used to determine the molecular weight or apparent molecular weight of uncharacterized molecules, such as proteins and nucleic acids, as well as in other applications. In one aspect, the molecular weight standards are pre-stained.07-19-2012
20100160607p16 MEDIATED REGULATION OF NMDA RECEPTORS - Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor.06-24-2010
20110196128MURINE ZCYTOR17 LIGAND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.08-11-2011
20130085264Methods and Reagents for Diagnosing Hantavirus Infection - Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.04-04-2013
20130085262NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from 04-04-2013
20080300384T-bet compositions and methods of use thereof - Isolated nucleic acid molecules encoding T-bet, and isolated T-bet proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet activity in a biological sample, methods of modulating T-bet activity in a cell, and methods for identifying agents that modulate the activity of T-bet.12-04-2008
20100113742Modified polypeptides stabilized in a desired conformation and methods for producing same - The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation.05-06-2010
20130085263METHOD FOR NON-COVALENT IMMOBILIZATION OF INFECTIOUS PRION PROTEIN - The present invention is method for non-covalently immobilizing an infectious prion protein using a magnetic substrate.04-04-2013
20130035472METHOD OF PRODUCING TRANSCRIPTS USING CRYPTIC SPLICE SITES - The invention is directed to a method of preparing a nucleic acid sequence with a modified splice site usage profile, which employs the use of a nucleic acid sequence comprising a cryptic splice donor site. The invention also provides a method of producing an alternate form of an RNA molecule encoded by a nucleic acid sequence, which nucleic acid sequence comprises a cryptic splice donor site, a heterologous nucleic acid sequence, and a splice acceptor site.02-07-2013
20100041870LYOPHILIZATION ABOVE COLLAPSE - The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.02-18-2010
20090156786Mammalian Genes: Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.06-18-2009
20100105867PROCESS FOR PRODUCING OSTEOCALCIN-CONTAINING EXTRACT - A process for producing an extract containing activated osteocalcin; an extract which can be obtained by this production process; a food, a drink, a drug, an oral cavity-care composition and a feed containing this extract; and a growth enhancer containing osteocalcin originating in a bone.04-29-2010
20100105865Nucleic acids and proteins from streptococcus groups a & b - The invention provides proteins from group B 04-29-2010
20100105868METHOD FOR DETECTING NEUROBLASTOMA - The present invention is intended to provide a means for judging the malignancy of neuroblastoma and the progress of spontaneous regression thereof. The present invention provides a method for detecting cancer which comprises detecting activation or inactivation of the lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) gene and amplification of the MYCN gene in a specimens to evaluate the malignancy of the specimens and the progress of spontaneous regression.04-29-2010
20100105866MICROFLUIDIC MANIPULATION OF FLUIDS AND REACTIONS - The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including microreactors for manipulating fluids and reactions. In some embodiments, structures and methods for manipulating many (e.g., 1000) fluid samples, i.e., in the form of droplets, are described. Processes such as diffusion, evaporation, dilution, and precipitation can be controlled in each fluid sample. These methods also enable conditions within the fluid samples (e.g., concentration) to be controlled. Manipulation of fluid samples can be useful for a variety of applications, including testing for reaction conditions, e.g., in crystallization, chemical, and biological assays.04-29-2010
20100145015COMPOSITIONS AND METHODS FOR INCREASING IMMUNOGENICITY OF GLYCOPROTEIN VACCINES - The present invention relates to the microbial immunogens engineered to bear α-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-Gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, Old World monkey or bird cells that have been engineered to express an α1,3galactosyltransferase (α 1,3GT) gene to produce virions bearing hemagglutinin molecules containing α-gal epitopes, to increase the immunogenicity of the influenza virus. In another embodiment, the present invention provides fusion proteins between influenza virus hemagglutinin and a microbial peptide or protein of interest, and enzymatic processing of this fusion protein to carry α-gal epitopes, to increase the immunogenicity of the microbial peptide or protein of interest.06-10-2010
20120165507MUTANT PROTEINS AND METHODS FOR PRODUCING THEM - A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a parent GPCR, wherein (i) the one or more mutations are located within a window of / plus or minus 5 residues, where / is the position of amino acid residue 2.46 in the parent GPCR when the parent GPCR is a Class 1 GPCR, or where / is the position of an equivalent amino acid residue in the parent GPCR when the parent GPCR is a Class 2 or 3 GPCR, and/or (ii) the one or more mutations are located within an amino acid sequence of transmembrane helix 7 in the parent GPCR which amino acid sequence interacts with the window of / plus or minus 5 residues, to provide one or more mutants of the parent GPCR with increased stability.06-28-2012
20130090454Light-Sensitive Ion-Passing Molecules - The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.04-11-2013
20090221794Human Protooncogene and Protein Encoded By Same - Disclosed are a novel protooncogene and a protein encoded by the same. The protooncogene of the present invention may be effectively used for diagnosing various cancers including breast cancer, leukemia, uterine cancer, malignant lymphoma, etc.09-03-2009
20090326200Altered ospa of borrelia burgdorferi - Provided herein are OspA polypeptides from Lyme Disease-causing 12-31-2009
20090306344METHOD OF REDUCING THE VISCOSITY OF MUCUS - Disclosed is a pO157 plasmid-specified polypeptide found in 12-10-2009
20130060007METHOD OF PROTEIN REFOLDING WITH ION EXCHANGE RESINS AND THE APPLICATION OF THE SAME - A method for protein refolding using a like-charged ion exchange resins as an additive to facilitate protein refolding. The ion exchange resins mentioned herein includes charged group with the same sign as the target protein to be refolded and the method for refolding an unfolded protein. The method has some advantages described as below: firstly, no new impurity is introduced into the final product of protein due to ion exchange resins used in the present invention is insoluble and easy to remove by settlement or centrifugation, secondly; the key material used in the present invention, ion exchange resins, is easy to recycle after regeneration; thirdly, compared with the refolding method by chromatographic techniques, the current method requires no expensive chromatograph facilities and is simple to perform at lower cost, which is a desirable character for preparative refolding of therapeutic proteins expressed in bacteria as inclusion bodies.03-07-2013
20120190821RECOMBINANT SOLUBLE FC RECEPTORS - Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.07-26-2012
20090270593NUCLEIC ACID BINDING SUBSTANCE CONTAINING CATALYTIC NUCLEATION NANOPARTICLES - A nucleic acid binding substance having an affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a catalytic nucleation particle10-29-2009
20090270591NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from 10-29-2009
20090270592Purified TNFR preparations - Purified protein preparations comprising tumor necrosis factor are disclosed.10-29-2009
20090270594USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ALLERGIES - The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies10-29-2009
20130066047RED-SHIFTED CHANNELRHODOPSINS - Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo.03-14-2013
20130066048Methods of Obtaining Natural Products from the Comestible Fluids and Methods of Use - Described herein is an enriched substance containing a ground edible material comprising one or more concentrated bioactive natural products from plant juice, as well as methods of producing such enriched substances and methods of using such solids to provide beneficial effects to humans or other animals. Enriched foods comprising the enriched substance(s) are also provided. Also provided are non-sorbed natural products such as sugars, fats oils, and carotenoids found in the non-sorbed plant liquor fraction of plant juice.03-14-2013
20100121031MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS - Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.05-13-2010
20090234101DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS - In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.09-17-2009
20090234100OSTEOGENIC COMPOSITIONS COMPRISING AN AMIONO ACID SEQUENCE WHICH IS CAPABLE OF BEING PHOSPHORYLATED BY CAMK2 - Novel osteogenic compositions and methods are provided. In a broad aspect, the composition comprises either a first amino acid sequence which is capable of being phosphorylated by CAMK2; or a nucleic acid sequence encoding the first amino acid sequence; or a combination thereof. Optionally, the first amino acid sequence may further comprise a second amino acid sequence which is capable of binding the Smurf1 protein. Further, the composition may comprise a BMP protein and/or an agent capable of decreasing an amount or an activity of CAMK2. The compositions of the instant invention may be incorporated into an implant or delivered via a catheter. 09-17-2009
20120116053EXPRESSION OF TRIPLE-HELICAL COLLAGEN-LIKE PRODUCTS IN E.COLI - Recombinant bacterial triple-helical collagen-like proteins comprising two or more repetitive sequences of Gly-Xaa-Yaa yielding high-stability polymeric constructs without the need for post-translational modifications and which may incorporate one or more functional domains of biological or structural importance. The polymers are capable of high-yield production for a variety of applications05-10-2012
20120116052Nucleic Acid Molecules Encoding TNF-Alpha Ligand Polypeptides Having a CD154 Domain - The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain replaces a cleavage site of native TNFα, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell.05-10-2012
20090012266Anti-TNFalpha Antibodies and Methods of Use - Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed.01-08-2009
20100087624Methods for making recombinant proteins using apoptosis inhibitors - The invention provided improved methods of making and producing recombinant proteins in in vitro cultures of host cells using apoptosis inhibitors. The use of one or more apoptosis inhibitors in the methods can reduce apoptosis in the cell cultures and markedly improve yield of the desired recombinant proteins.04-08-2010
20090192291PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS - The present invention provides method for producing trimeric tumor necrosis factor receptors that are potent inhibitors of their cognate ligands. More particularly, the present invention provides polypeptides that comprise: (1) an extracellular domain of the transmembrane activator and CAML (calcium-signal modulating cyclophilin ligand) interactor (TACI), and (2) a trimerizing polypeptide. Suitable TACI extracellular domains include: (1) amino acid residues 30 to 110 of SEQ ID NO:4, (2) amino acid residues 1 to 110 of SEQ ID NO:4, (3) amino acid residues 30 to 154 of SEQ ID NO:4, and (4) amino acid residues 1 to 154 of SEQ ID NO:4. Illustrative trimerizing polypeptides include a trimerizing fragment of Heat Shock Binding Protein-1. The present invention further provides homotrimeric complexes of fusion proteins comprising a TACI extracellular domain and a trimerizing polypeptide.07-30-2009
20120238726Mutant blue fluorescent protein and method of using the same for fluorescence resonance energy transfer and blue fluorescent fish - The present invention discloses a mutant blue fluorescent protein (BFP), mutated by an error-prone PCR method or a DNA shuffling method with using a BFPvv D7 of SEQ ID NO:2 as parents, obtained from a wild type blue fluorescent protein BfgV of SEQ ID NO:1, obtained from 09-20-2012
20110028689NUCLEIC ACIDS THAT ENCODE SODIUM CHANNEL - A method or screen for assessing the potential of a compound to treat a pathological condition, such as arrhythmia, which is manifested by an increased late sodium current in a heart is disclosed. The method employs a mutant sodium channel protein having an amino acid sequence in which one or more amino acids among the ten amino acids occurring at the carboxy end of the S6 segments of D1, D2, D3 or D4 domains of mammalian Nav1 differs from the amino acid in wild-type Nav1 by substitution with tryptophan, phenylalanine, tyrosine or cysteine. Cells transfected with a nucleic acid that encodes a mutant mammalian Nav1 protein, as well as isolated nucleic acid comprising a nucleotide sequence that codes for a mutant mammalian Nav1 protein are disclosed.02-03-2011
20130165633Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors - The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.06-27-2013
20110245464HIGHLY THERMOSTABLE FLUORESCENT PROTEINS - Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a TSFP of the invention is so stable it can be heated to 99° C. for short periods of time without denaturing, and retains 85% of its fluorescence when heated to 80° C. for several minutes. The invention also provides a method for generating stability-enhanced variants of a protein, including but not limited to fluorescent proteins.10-06-2011
20100267929PRRS Viruses, Infectious Clones, Mutants Thereof, and Methods of Use - The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORF1 that encodes the nsp2 polypeptide.10-21-2010
20100022751RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.01-28-2010
20100234569AQUEOUS PROCESSING OF OILSEED PRESS CAKE - The subject invention relates in part to novel steps in canola and other oil seed processing, including milling to achieve a significant particle size reduction, extraction of higher levels of protein from the starting material, the use of presscake as a starting material, and the production of a precipitated protein concentrates containing a nutritionally significant amount of oil. The subject invention also provides optimal pH ranges for extraction and recovery steps in these novel processes. The subject processes can be applied to, and offer similar advantages to, other oilseeds and vegetable matter, such as sunflower seeds and flax seeds. The subject invention also includes novel feed compositions.09-16-2010
20130023647MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN - Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.01-24-2013
20110301328POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.12-08-2011
20090124790CHROMATOGRAPHIC METHOD AND SYSTEM FOR PURIFYING A BOTULINUM TOXIN - Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.05-14-2009
20110288272MODIFIED CRY3A TOXINS AND NUCLEIC ACID SEQUENCES CODING THEREFOR - Methods for making a modified Cry3A toxin are disclosed. Such methods include the insertion of a protease recognition site that is recognized by a gut protease of a target insect, such as corn rootworm, into at least one position of a Cry3A toxin so that a modified Cry3A toxin is thus designed. The coding sequence of the modified Cry3A toxin may be transformed into a host cell and the host cell grown under conditions that allow the host cell to produce the modified Cry3A toxin. The host cell may be a plant cell and the plant may be comprised in a transgenic plant. Thus, the transgenic plant may be used to produce the modified Cry3A toxin.11-24-2011
20110294983SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS - The present invention relates to single-chain proteins of the formula HRS1-L1-HRS2-L2-HRS3, wherein HRS1, HRS2 and HRS3 are heptad repeat sequences and L1 and L2 are structurally flexible linker sequences, and wherein HRS1, HRS2 and HRS3 form a thermodynamically stable triple-stranded, antiparallel, alpha-helical coiled coil structure in aqueous solution. The invention also relates to amino acid sequence variants, conditions and methods to obtain such proteins and variants, and us ages thereof, especially their usage as scaffolds and as therapeutic products.12-01-2011
20110294981CHIMERIC T1R TASTE RECEPTOR POLYPEPTIDES AND NUCLEIC ACID SEQUENCES ENCODING AND CELL LINES THAT EXPRESS SAID CHIMERIC T1R POLYPEPTIDES - The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging.12-01-2011
20110294982AMINO ACID SEQUENCES DIRECTED AGAINST INTEGRINS AND USES THEREOF - The present invention relates to amino acid sequences that are directed against (as defined herein) Integrins, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 12-01-2011
20100010195Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same - The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.01-14-2010
20100036096COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT PROTEINS - A class of integral membrane proteins, referred to as Mistic polypeptides, their variants, fusion proteins including a Mistic polypeptide domain, and nucleic acid molecules encoding Mistic polypeptides and Mistic fusion proteins are disclosed herein. Also described are methods of using Mistic polypeptides and Mistic fusion proteins to produce and/or isolate recombinant proteins (including without limitation classes of eukaryotic proteins that have previously been intractable to recombinant bacterial expression, such as, eukaryotic integral membrane proteins).02-11-2010
20100036095Human CD59 mutants with modulated complement binding activity - Disclosed are compositions and methods using mutant CD59. Also disclosed is new insight into the CD59-C8/C9 binding interface and engineered soluble CD59 molecules with significantly improved complement inhibitory activity.02-11-2010
20120190822ARTIFICIAL ENTROPIC BRISTLE DOMAIN SEQUENCES AND THEIR USE IN RECOMBINANT PROTEIN PRODUCTION - Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production.07-26-2012
20120065372DRAGLINE PROTEIN - To provide a new natural fiber material with excellent physical properties. Any one of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence of SEQ ID NO: 1 or 19; (b) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2 or 20; (c) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (a); (d) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (a) under stringent conditions.03-15-2012
20100048871Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids - Modified biosynthetic polypeptide molecules, methods for manufacturing, and uses thereof are provided.02-25-2010
20090221797HETEROMERIC TASTE RECEPTORS - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R1 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R1 polypeptide or a different GPCR; and a second polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R3 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R3 polypeptide or that of a different GPCR.09-03-2009
20090221795ACTIVE TRUNCATED FORM OF THE RNA POLYMERASE OF FLAVIVIRUS - The isolation and purification of two domains from a from a 09-03-2009
20100249377ENGINEERED HYBIRD PHAGE VECTORS FOR THE DESIGN AND THE GENERATION OF A HUMAN NON-ANTIBODY PEPTIDE OR PROTEIN PHAGE LIBRARY VIA FUSION TO pIX OF M13 PHAGE - The invention relates to a compositions and methods for generating and using pIX phage display libraries for producing non-antibody peptide or protein proteins or peptides using engineered hybrid phage vectors derived from pIX of M 13 phage09-30-2010
20100249376NELL Peptide Expression Systems and Bone Formation Activity of NELL Peptide - The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.09-30-2010
20110263822COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF HBV INFECTIONS AND HBV-MEDIATED DISEASES - The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and/or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and/or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding that antigen. The present invention also includes pharmaceutical compositions, especially vaccines, comprising these compositions for the prevention and/or treatment of an HBV infection or an HBV-mediated disease. The present invention further includes a method of preparing a patient-specific medicament for the therapeutic treatment of hepatitis B.10-27-2011
20090149633ARTIFICIAL DIET FOR LEPIDOPTERAN INSECTS AND PRODUCTION METHOD THEREOF, LEPIDOPTERAN INSECT AND PRODUCTION METHOD THEREOF, AND BIOLOGICAL MATERIAL - An artificial diet for lepidopteran insects of the present invention, including: a protein; and a carbohydrate, wherein a content of a stable isotope is equal to or greater than 50 atom %. A method for producing an artificial diet for lepidopteran insects, including: a defatting treatment step of subjecting a microorganism to a defatting treatment; a hydrothermal solution extraction treatment step of subjecting the microorganism to an extraction treatment using a hydrothermal solution; and a mixing step of mixing a carbohydrate and a protein originated from the microorganism that is subjected to the defatting treatment step and the hydrothermal solution extraction treatment step.06-11-2009
20100267930SLO2 and SLO4, Novel Potassium Channel Proteins from Human Brain - The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.10-21-2010
20080287656Device and Method For Cell Free Analytical and Preparative Protein Synthesis - A device is disclosed which contains one or more pores 11-20-2008
20100121030ANTAGONISM OR EVASION OF SOLUBLE CYTOKINE RECEPTORS - Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.05-13-2010
20100137563Cysteine Protease Autoprocessing of Fusion Proteins - Disclosed are fusion proteins, polynucleotides that encode the disclosed fusion proteins, and methods for expressing and autoprocessing of the disclosed fusion proteins to obtain a target protein. The disclosed fusion proteins include an autoproteolytic cysteine protease fused to a heterologous polypeptide, which may be isolated as the target protein. Preferably, the protease activity of the cysteine protease is inducible. Suitable autoproteolytic cysteine proteases for the fusion proteins include the cysteine protease of the 06-03-2010
20120226022HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS - The present invention is directed to conjugates of hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors.09-06-2012
20120108792PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.05-03-2012
20120108791Rotamer Libraries and Methods of Use Thereof - Rotamer libraries and methods of use thereof are provided.05-03-2012
20120108790Truncated Somatostatin Receptors - The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.05-03-2012
20120108789High affinity binding site of HGFR and methods for identification of antagonists thereof - Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.05-03-2012
20100087625METHOD OF ENHANCING RECOMBINANT PROTEIN PRODUCTION - The present invention provides a method of enhanced protein production that comprises the step of expressing a recombinant gene encoding the protein in eukaryotic cells under conditions in which cleavage of the pro-domain of the protein is inhibited or eliminated. Generally the method of the present invention includes the step of inhibiting or altering the cleavage of a pro-domain of a recombinant protein of interest in order to increase the amount of recombinant protein secreted from a eukaryotic cell. Recombinant proteins that can be prepared using the method of this invention include members of the transforming growth factor-β (TGF-β) superfamily, such as bone morphogenetic proteins. Also provided are genetically engineered cells and polynucleotides for performing the method of the invention.04-08-2010
20100099848RANKL PRODUCTION INHIBITOR - The production of RANKL may be inhibited by orally ingesting a milk-derived basic protein. Thus, a RANKL production inhibitor containing a milk-derived basic protein fraction as an active ingredient; a therapeutic agent for a metabolic bone disease and a therapeutic agent for an immune disease each containing the RANKL production inhibitor; and a food/beverage and a feed each containing a specified amount of the RANKL production inhibitor and being characterized by inhibiting the production of RANKL have a remarkable effect of inhibiting the production of RANKL, can be ingested on a daily basis, and exhibit high safety even when being ingested over a long period.04-22-2010
20110201782NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.08-18-2011
20090259024GLUCOSE DEHYDROGENASE FROM ASPERGILLUS ORYZAE - The present invention effectively produces glucose dehydrogenase derived from 10-15-2009
20110172393NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.07-14-2011
20100125129Thermostable Fusion Proteins and Thermostable Adjuvant - Fusion proteins including maltodextrin-binding protein (MBP) domains that are thermally stable and soluble are provided. Methods for forming and using the fusion proteins are also provided.05-20-2010
20090286957NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF BREAST CANCER - Novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.11-19-2009
20100280223 METHOD FOR DETERMINING AND PREDICTING PROTEIN AUTONOMOUS FOLDING - Techniques for determining an equilibrium structure of a protein in a predetermined environment, the protein having Ramachandran angles and a known denatured structure, are disclosed. In a preferred embodiment, a method is presented which involves determining a maximum RMS volume of the known denatured structure of the protein and calculating at least one force on the protein in its current structure in the predetermined environment. The net torque resulting from the at least one force for each of the Ramachandran angles of the protein is then determined. Then at least one section of the protein structure on a side of a Ramachandran angle with greatest torque is rotated to form a new structure. A new RMS volume for the new structure is then calculated, and the method is repeated using the new structure. The method ceases when the new RMS volume of the new protein structure is not less than the RMS volume of the starting structure.11-04-2010
20100280225FUNGUS-INDUCED INFLAMMATION AND EOSINOPHIL DEGRANULATION - This document relates to methods and materials involved in fungus-induced inflammation and eosinophil degranulation. For example, isolated nucleic acids encoding fungal polypeptides, fungal polypeptides, methods for assessing fungus-induced inflammation, methods for assessing eosinophil degranulation, and methods for identifying inhibitors of fungus-induced inflammation and/or eosinophil degranulation are provided.11-04-2010
20100280222CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS - Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.11-04-2010
20110269939NEW APPROACH FOR DESIGNING DIABETES DRUGS - The present technology relates to the fields of crystallography, biochemistry, and drug design. In particular, methods and compositions for screening, identifying and designing compounds that interact with human mitoNEET.11-03-2011
20080207877Modified Human Four Helical Bundle Polypeptides and Their Uses - Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.08-28-2008
20080275217Proteins Having Effects Of Controlling Cell Migration And Cell Death - The present invention relates to which have a role in controlling neuronal cell migration and cell death as well as to the DNA which encode those proteins. It is an object of the present invention to provide control of cell migration and/or cell death by providing a method for screening for promoters or inhibitors of proteins which affect the control of cell migration and/or cell death of neurons by interacting with an actin-binding protein, Filamin 1, through promoting the degradation of Filamin 1 or the DNA encoding Filamin 1. The cDNAs of S-FILIP, L-FILIP and h-FILIP cDNAs, which interact with Filamin 1, thereby negatively affecting cell migration and cell death by promoting the degradation of the Filamin 1, were isolated and the full nucleotide and amino acid sequences thereof were determined.11-06-2008
20110207912FGF-19 NUCLEIC ACIDS - The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation.08-25-2011
20080306244Renta: an HIV immunogen and uses thereof - The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, including Reverse Trancriptase (RT), Env (gp41), Nef and Tat proteins, as well as at least one HIV CTL epitope associated with long-term, non-progression to AIDS; these domains are biologically-inactivated for one or more of the normal activity of those proteins or are partial protein sequences (and similarly biologically-inactivated). RENTA is an AFP in which the HIV domains are from an HIV Clade A consensus sequence and contains additional domains, useful for example, in monitoring expression levels or laboratory animal immune responses. Such domains are optionally included in the AFPs. Other aspects of the invention may include compositions for and methods of inducing an anti-HIV immune response in a subject, preferably using a DNA prime-MVA boost strategy, and preferably to induce a cell-mediated immune response.12-11-2008
20080312413COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS - The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof to treat cancer in mammals.12-18-2008
20080242839HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”10-02-2008
20080275218LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like.11-06-2008
20080319167Clostridial toxin derivatives able to modify peripheral sensory afferent functions - This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.12-25-2008
20080312412Chimeric immunogens - Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.12-18-2008
20080214784HUMAN T1R2 TASTE RECEPTOR POLYPEPTIDES - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.09-04-2008
20090264624HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”10-22-2009
20090264623SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.10-22-2009
20090264622Rhesus monkey Nur7710-22-2009
20100137562MAVS IN THE PREVENTION AND TREATMENT OF VIRAL DISEASE - The present invention includes compositions and methods for the identification, characterization and use of a novel anti-viral protein that includes a mitochondrial anti-viral signaling protein.06-03-2010
20110269940Self-Assembled Proteins and Related Methods and Protein Structures - The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of gene sequences that transcribe peptide sequences that form links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of homo-dimers, hetero-dimers and multimers of the proteins to which they are attached. The hook or loop may have a short aliphatic repeat sequence and a metal binding loop. The present invention also provides a method of constructing a hook motif of metal binding loop sequences that may be attached to at least one aliphatic repeat sequence to produce the assemblages of proteins. Also provided are protein structures produced by the methods of the present invention.11-03-2011
20090054626CRUSTACEAN-DERIVED PROTEIN HAVING ANTIFREEZE ACTIVITY - A crustacean-derived protein having antifreeze activity which under reduced conditions has a molecular weight, as measured by sodium dodecyl sulfate (SDS)—polyacrylamide gel electrophoresis, of about 37,000, about 16,000, and/or about 15,400; and the N-terminal amino acids are indicated by SEQ ID No. 1 or SEQ ID No. 2.02-26-2009
20090030182ACTIVATABLE RECOMBINANT NEUROTOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.01-29-2009
20090088557NOVEL SEMAPHORIN GENES (I) - The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, transformed cells into which said expression vectors have been introduced, methods for producing a recombinant protein which employ said transformed cells, antisense nucleotides against the above genes, transgenic animals involving insertion or deletion of the above genes, and screening methods for antagonists of the above proteins, all of which are useful mainly in diagnoses, treatments, or studies relating to neurological diseases. The present invention further provides use of such proteins, peptides, antibodies, genes, or antisense nucleotides as pharmaceutical or diagnostic agents or laboratory reagents.04-02-2009
20090182121Regulation of Human Transmembrane Serine Protease - Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.07-16-2009
20090182124NOVEL TRANSCRIPTION FACTOR HAVING ZINC FINGER DOMAINS - Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant homology to the Sp1 family genes. Furthermore, a human gene corresponding to this mouse gene was isolated. The protein encoded by this gene existed in the nucleus and bonded to a GC-box. The protein was revealed to repress the transcription regulatory activity of the CMV promoter and thus serves as a transcription factor.07-16-2009
20090182122NUCLEIC ACID SEQUENCES ENCODING TRANSCRIPTION FACTOR PROTEINS - Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants.07-16-2009
20090005538Apoptosis-Inducing Agent for Prostate Cancer Cells - According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC/Dkk-3 DNA or an REIC/Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided.01-01-2009
20090005537Process for constructing strain having compactin hydroxylation ability - The present invention is directed to methods and compositions for microbial based production of pravastatin. The compositions of the invention include novel strains of microorganisms that are capable of efficiently hydroxylating compactin (ML-236 B) resulting in production of pravastatin. In particular, the microorganisms of the invention are genetically engineered to express both cytochrome P-450 and the fdxshe or fdxshe-like protein. The invention further relates to the use of such microorganisms in processes designed for production of pravastatin for use in treatment of disease such as hypercholesterolemia and hyperlipidemia.01-01-2009
20090187006NOVEL PROTEIN, A GENE ENCODING THEREFOR AND A METHOD OF USING THE SAME - An object of the present invention is to search and identify novel antifungal proteins capable of inhibiting the growth of plant pathogenic microorganisms including 07-23-2009
20090062513PRODUCTION OF BYPOLYMER FILM, FIBRE, FOAM AND ADHESIVE MATERIALS FROM SOLUBLE S-SULFONATED KERATIN DERIVATIVE - Film, fibre, foam and adhesive materials are produced from soluble S-sulfonated keratins. Once formed, the films, fibres, foams or adhesives are treated to modify the properties of the materials, in particular to improve the wet strength of the materials. Treatments used include removal of the S-sulfonate group by treatment with a reducing agent, treatment with an acid or treatment with a common protein crosslinking agent or treatment with a reduced form of keratin or keratin protein. The films are made by solvent casting a solution of S-sulfonated keratin proteins, the foam made by freeze-drying a solution of S-sulfonated keratin proteins and the fibres made by extruding a solution of a S-sulfonated keratin protein.03-05-2009
20080319169Biomimetic materials for protein storage and transport - The invention provides a method for the insertion of protein in storage vehicles and the recovery of the proteins from the vehicles, the method comprising supplying isolated protein; mixing the isolated protein with a fluid so as to form a mixture, the fluid comprising saturated phospholipids, lipopolymers, and a surfactant; cycling the mixture between a first temperature and a second temperature; maintaining the mixture as a solid for an indefinite period of time; diluting the mixture in detergent buffer so as to disrupt the composition of the mixture, and diluting to disrupt the fluid in its low viscosity state for removal of the guest molecules by, for example, dialysis, filtering or chromatography dialyzing/filtering the emulsified solid.12-25-2008
20080319168Method for Coating Surfaces with Hydrophobins - A method for coating surfaces with hydrophobin fusions at a pH of ≧4, and a surface having a coating which comprises at least one hydrophobin fusion.12-25-2008
20100267931HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS - Alternative and improved approaches to the heterologous expression of the proteins of 10-21-2010
20130217859CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB 1870 is a protein in 08-22-2013
20090198042POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.08-06-2009
20110230643RECOMBINANT FLAGELLIN PROTEIN AND PREPARATION AND USE THEREOF - The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliCΔ190-278, FliCΔ220-320 or FliCΔ180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.09-22-2011
20090192292MURINE ZCYTOR17 LIGAND POLYPEPTIDES AND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.07-30-2009
20090192290New bacillus thuringiensis strains and their insecticidal proteins - Four novel 07-30-2009
20110230642METHOD FOR INCREASING RECLONING EFFICIENCY - The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells.09-22-2011
20090054624PRO1190 POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to CDO protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.02-26-2009
20080262202NOVEL CANCER-ASSOCIATED GENES - The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible to inhibit cancer by blocking the binding of the present protein to its ligand. Accordingly, the present antibody is used not only in the detection of the present protein, but also as an agent for the treatment or prevention of cancers such as prostatic adenocarcinoma and ovarian carcinoma.10-23-2008
20090203885Astrocyte Modulated Genes And Uses Thereof - The present invention relates to Astrocyte Modulated Genes (AMGs). AMGs are genes whose expression are modulated in human astrocytes grown in primary cell culture following the exposure of these cells to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120. AMGs comprise both Astrocyte Enhanced Genes (AEGs) and Astrocyte Suppressed Genes (ASGs). Thus, the present invention further relates to Astrocyte Enhanced Genes (AEGs), the expression of which are up-regulated in human astrocytes grown in primary cell culture that are exposed to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120, and to Astrocyte Suppressed Genes (ASGs), the expression of which are downregulated in human astrocytes grown in primary cell culture that are exposed to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120. Because they may play a role in HIV-associated dementia (“HAD”), AMGs may be used as markers in methods for screening for drugs that treat or prevent HAD.08-13-2009
20090203884CHIMERIC HIV FUSION PROTEINS AS VACCINES - A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included.08-13-2009
20090203883MUSSEL BIOADHESIVE - The present invention relates to a bioadhesive derived from mussel. In particular, it relates to a novel MGFP-3A MUTANT (08-13-2009
20120077960FLUOROBODIES: INTRINSICALLY FLUORESCENT BINDING LIGANDS - Binding ligands with intrinsic fluorescence (“fluorobodies”), fluorobody libraries, and methods of preparing fluorobodies are provided. In one aspect, the invention provides fluorobodies generated from a highly stable, artificial fluorescent protein, eCGP123 and derivatives thereof.03-29-2012
20090221799Novel Fluorescent and Colored Proteins, and Polynucleotides That Encode These Proteins - The subject invention provides new fluorescent and/or colored proteins, and polynucleotide sequences that encode these proteins. The subject invention further provides materials and methods useful for expressing these detectable proteins in biological systems.09-03-2009
20090203882NOVEL MICROBIAL ENZYMES AND THEIR USE - Extracellular tyrosinases obtainable from 08-13-2009
20090209731Heteromeric taste receptors - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide containing extracellular domains and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R1 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R1 polypeptide or a different GPCR; and a second polypeptide comprising extracellular and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R3 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R3 polypeptide or a different GPCR.08-20-2009
20090209729Recombinant chemokine-antigen vaccine - A recombinant gene sequence that comprises human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment is linked downstream to the antigen gene. This invention also relates to the application of the recombinant gene sequence in the preparation of gene vaccine.08-20-2009
20090240035DNA REPLICATION PROTEINS OF GRAM POSITIVE BACTERIA AND THEIR USE TO SCREEN FOR CHEMICAL INHIBITORS - The present invention relates to alpha-large, alpha-small, delta, delta prime, tau, beta, SSB, DnaG, and DnaB encoding genes from Gram positive bacterium, preferably 09-24-2009
20090253898Mathematical Design of ION Channel Selectivity Via Inverse Problem Technology - Determining the structure of permanent charge for an ion channel formulates an abstract operator, describing ion channel parameters, comprising equations that are ill-posed. The model of ion channel behavior relates the function of the ion channel to the structure of permanent charge within the ion channel and concentrations ions around the ion channel under certain properties and boundary conditions. The model also includes regularization of the abstract operator by approximating the ill-posed equations with a family of well-posed equations. An estimate of the closeness of the well-posed solution to the ill-posed solution is provided. Providing stable and convergent algorithms allows the model to determine a stability for the regularized solution, so that a regularization parameter can determine a balance between the stability and accuracy of the solution.10-08-2009
20120197005CONTAINERLESS SYNTHESIS OF AMORPHOUS AND NANOPHASE ORGANIC MATERIALS - The invention provides a method for producing a mixture of amorphous compounds, the method comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point. Also provided is a method for transforming solids to amorphous material, the method comprising heating the solids in an environment to form a melt, wherein the environment contains no nucleation points; and cooling the melt in the environment.08-02-2012
20090182123Method of Preparing Botulinum Neurotoxin Type E Light Chain - The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.07-16-2009
20090259023LIQUID BUFFERED GDF-5 FORMULATIONS - Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use.10-15-2009
20090259022CDNA ENCODING THE HUMAN ALPHA2 DELTA4 CALCIUM CHANNEL SUBUNIT - The present invention provides nucleic acid and polypeptide sequences describing an isoform of the α2δ-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional α2δ-4 protein. The calcium channel α2δ-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.10-15-2009
20100168389PROCESS FOR PRODUCING EXTRACT FOR CELL-FREE PROTEIN SYNTHESIS AND CELL EXTRACT PRODUCED THEREBY - It is intended to provide a process for producing an extract for cell-free protein synthesis whereby the productivity of a protein and the production efficiency can be improved. Cells are cultured under suppressed growth conditions. In the stationary phase of the culture, the cells are collected and then disrupted. The above-described cells are preferably bacterial cells, in particular, 07-01-2010
20090048431MULTIVALENT CLOSTRIDIAL TOXINS - The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.02-19-2009
20100261883BONE RESORPTION INHIBITORY FOOD MATERIAL FOR INHIBITING BONE RESORPTION - A milk protein fraction having following properties (1) to (4) is excellent in bone resorption inhibitory effect, and is useful for preventing or treating bone diseases: 10-14-2010
20100261884CLOSTRIDIUM PERFRINGENS ALPHA TOXIN PROTEINS - This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic 10-14-2010
20100261881MARKER SEQUENCES FOR RHEUMATOID ARTHRITIS AND USE THEREOF - The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof.10-14-2010
20110060127Structure Of Compstatin-C3 Complex And Use For Rational Drug Design - The structure of C3c in complex with the complement inhibitor, compstatin, and use of this information for rational design or identification of complement-inhibiting drugs are disclosed.03-10-2011
20110060126METHOD AND APPARATUS FOR OPTIMIZING CRYSTALLIZATION CONDITIONS OF A SUBSTRATE - The present invention relates to a multi-well crystallization plate comprising a plurality of wells, each well having therein a different crystallization media. Each crystallization media varying according to at least two different parameters. The first parameter has at least one condition, and the second parameter has at least two different conditions, whereby the multi-well plate allows facilitating optimization of crystallization conditions of a substrate. Methods for optimizing crystallization conditions of a substrate are also disclosed.03-10-2011
20120142895HOST CELLS AND METHODS OF USE - The present invention provides genetically modified 06-07-2012
20100160609Chimera Botulinum Toxin Type E - The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.06-24-2010
20130123467Engineering surface epitopes to improve protein crystallization - The invention provides for methods and systems for engineering target proteins, based on protein sequence characteristics that influence the likelihood of obtaining a crystal suitable for X-ray structure solution, to improve protein crystallization, as well as related material.05-16-2013
20100240869GENE RELATED TO GROWTH PROMOTING FUNCTION OF ACETIC ACID BACTERIUM, ACETIC ACID BACTERIUM BRED USING THE GENE AND METHOD FOR PRODUCING VINEGAR USING THE ACETIC ACID BACTERIUM - The present invention is to obtain a novel gene that encodes a protein having a function of promoting acetic acid bacterial growth in the presence of a high concentration of acetic acid; to enhance acetic acid bacteria's function of promoting growth and thereby to develop acetic acid bacteria with an improved fermentation ability in the presence of a high concentration of acetic acid; and to provide a method for efficiently producing vinegar that contains a high concentration of acetic acid in a short time using the acetic acid bacterium. A novel gene having a function of improving the function of promoting growth at a practical level was cloned from acetic acid bacteria for practical use, belonging to the genus 09-23-2010
20100240868Composition and Method for a Producing Stable Amyloid Beta Oligomers of High Molecular Weight - The invention relates to a method for the preparation of a stable, soluble amyloid beta (Aβ) oligomer and composition thereof for use as an antigen for the generation of antibodies for the treatment of Alzheimer's disease and other conditions related to abnormal amyloid beta aggregation. The method which uses a pH in excess of 7.0 and high concentrations of Aβ, optionally includes the use of divalent anions or a helix-inducing solvent to form the oligomers. The stable, soluble Aβ oligomers produced by the method herein have a particle size of 10 to 100 nm in diameter, when measured by a dynamic light scattering technique, and a molecular weight of 100 to 500 kDa.09-23-2010
20100222551Highly thermostable fluorescent proteins - Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a TSFP of the invention is so stable it can be heated to 99° C. for short periods of time without denaturing, and retains 85% of its fluorescence when heated to 80° C. for several minutes. The invention also provides a method for generating stability-enhanced variants of a protein, including but not limited to fluorescent proteins.09-02-2010
20090076245HIV-1 Subtype Isolate Regulatory/Accessory Genes, and Modification and Derivatives Thereof - The invention describes HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof. The genes which are described are the tat, nef and rev genes. Consensus amino acid sequences are also disclosed. The invention also relates to a vaccine including two or more of the nucleotide sequences, and nucleotide sequences from the pol and/or gag genes of HIV-1.03-19-2009
20100145016COMPOSITIONS AND METHODS FOR PURIFYING CALRETICULIN - The present invention relates to compositions, methods for expressing, and related methods for purifying calreticulin that is free of an affinity label or tag (i.e., non-tagged calreticulin). The invention provides useful methods for commercial production of human calreticulin in a bacterial expression system such as 06-10-2010
20100210819Biosensors to measure InsP3 concentration in living cells - Phosphoinositides participate in many signaling cascades via phospholipase C stimulation, which hydrolyzes phosphatidylinositol bisphosphate, producing second messengers diacylglycerol and inositol 1,4,5-trisphosphate (InsP08-19-2010
20100210820PROTEIN REFOLDING COLUMN FILLER AND COLUMN - It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in 08-19-2010
20100204451INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED - The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.08-12-2010
20110028691RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays.02-03-2011
20100099849INTERLEUKIN-17 RECEPTOR HOMOLOGUE - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.”04-22-2010
20090259025Lactoferrin - A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the mixture.10-15-2009
20120245324PROCESS FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.09-27-2012
20090105454Prophylactic/therapeutic agent for cancer - A compound or its salt that regulates (preferably inhibits) the activity of a protein comprising the same or substantially the same amino acid sequence as represented by SEQ ID NO: 1, a compound or its salt that regulates (preferably inhibits) the expression of a gene for the protein, an antisense polynucleotide comprising the entire or part of a base sequence complementary or substantially complementary to a base sequence of a polynucleotide encoding the protein or its partial peptide, an antibody against the protein, etc. can be used as a prophylactic/therapeutic agent for cancer, etc., an apoptosis inducing agent, or the like.04-23-2009
20090105453Interleukin-9 receptor mutants - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.04-23-2009
20130131315AUTO-PROCESSING DOMAINS FOR POLYPEPTIDE EXPRESSION - Embodiments herein include methods and constructs that can be used to co-express two or more polypeptides of interest from a single polynucleotide encoding a precursor polypeptide. Within this precursor polypeptide can reside at least one autonomous processing unit, which can mediate release of flanking polypeptides of interest in cis. The processing unit can include an N-terminal autocatalytic cleavage domain and a C-terminal cleavage domain. Some embodiments include constructs and methods for co-expressing polypeptides without N- or C-terminal overhangs, in any cellular or extracellular location, and/or in stoichiometric ratios.05-23-2013
20090069539Androgen regulated prostate specific nucleic acids - The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.03-12-2009
20130144038CRYSTAL STRUCTURE OF A MarR FAMILY POLYPEPTIDE - The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in 06-06-2013
20110009597RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF - Provided are the use of the recombinant 01-13-2011
20110034671Systems for Expression of Heterologous Proteins in M. Capsulatus - The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferably 02-10-2011
20100331523Heterologous Protein Production Using The Twin Arginine Translocation Pathway - Provided are means for evaluating and identifying putative substrates of the twin arginine translocation (Tat) secretory pathway in 12-30-2010
20110130543CHOLESTEROL CONSENSUS MOTIF OF MEMBRANE PROTEINS - The invention provides the structure of a human β2-adrenergic receptor, a cholesterol consensus motif, and methods of identifying modulators of G-protein coupled receptors (GPCRs). Methods of using the modulators of the receptor, GPCRs, and the cholesterol consensus motif are also provided.06-02-2011
20090054625RECOMBINANT PROTEIN VARIANTS - The present invention relates to novel recombinant protein variants that are useful as immunotherapeutic components. Also the present invention relates to DNA sequences encoding said protein variants as well as compositions comprising said protein variants.02-26-2009
20100069611CYTOLETHAL DISTENDING TOXINS AND DETECTION OF CAMPYLOBACTER BACTERIA USING THE SAME AS A TARGET - The present inventors succeeded in cloning the CDT genes of 03-18-2010
20110245465Methods for Detection of Methyl-CpG Dinucleotides - The invention provides methods for enriching methyl-CpG sequences from a DNA sample. The method makes use of conversion of cytosine residues to uracil under conditions in which methyl-cytosine residues are preserved. Additional methods of the invention enable to preservation of the context of me-CpG dinucleotides. The invention also provides a recombinant, full length and substantially pure McrA protein (rMcrA) for binding and isolation of DNA fragments containing the sequence 5′-C10-06-2011
20110245463APPARATUS AND METHOD FOR STRUCTURE-BASED PREDICTION OF AMINO ACID SEQUENCES - The present invention provides methods and apparatus for analyzing a protein structure.10-06-2011
20090221796Heteromeric taste receptors - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide containing extracellular domains and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R2 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R2 polypeptide or a different GPCR; and a second polypeptide comprising extracellular and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R3 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R3 polypeptide or a different GPCR.09-03-2009
20090221798HETEROMERIC TASTE RECEPTORS - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R2 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R2 polypeptide or a different GPCR; and a second polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R3 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R3 polypeptide or that of a different GPCR.09-03-2009
20100069610SUBSTRATES USEFUL FOR FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TXOINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.03-18-2010
20110178274CANINE TRANSIENT RECEPTOR POTENTIAL V2 (CTRPV2) AND METHODS OF SCREENING FOR TRPV2 CHANNEL MODULATORS - A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.07-21-2011
20090215989Heterologous Protein Production Using The Twin Arginine Translocation Pathway - Provided are means for evaluating and identifying putative substrates of the twin arginine translocation (Tat) secretory pathway in 08-27-2009
20110152502FLUORESCENT PROTEIN - The object of the present invention is to provide a novel fluorescent protein in which on and off of fluorescence thereof can be controlled by irradiation with lights of two different wavelengths. The present invention provides a fluorescent protein shown in the following (a) or (b);06-23-2011
20110152500Bipodal-Peptide Binder - The present invention deals with a bipodal-peptide binder that specifically binds with a target including (a) a structure stabilizing region that includes parallel, antiparallel or parallel and antiparallel amino acid strands wherein interstrand non-covalent bonds are formed; and (b) a target binding region I and a target binding region II that are bonded at both terminals of said structure stabilizing region and respectively include n and m amino acids, and a method of preparing same; the bipodal-peptide binder of the present invention exhibits the KD value (dissociation constant) of a very low level (for example, nM level) and, therefore, exhibits very high affinity toward a target. The bipodal-peptide binder of the present invention has applications not only in pharmaceuticals but also in in-vivo imaging, in vitro cell imaging, and drug delivery targeting, and can be very usefully employed as an escort molecule.06-23-2011
20110098447Homogenous Populations of Molecules - The invention provides populations of molecules that are prepared as, or treated to become, homogeneous for one or more molecular characteristics. In an aspect, the invention relates to molecular weight standards that may be used to determine the molecular weight or apparent molecular weight of uncharacterized molecules, such as proteins and nucleic acids, as well as in other applications. In one aspect, the molecular weight standards are pre-stained.04-28-2011
20120202971LIGHT ACTIVATED ASSOCIATION OF SPLIT GFP - The disclosure relates to a split GFP protein. The GFP protein includes a truncated strand and a beta strand (β-strand). The truncated GFP and the synthetic β-strand respond to the presence of light by changing an assembly thereof08-09-2012
20100261880LY6H POLYPEPTIDE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like.10-14-2010
20100261882METHOD AND APPARATUS FOR ASSESSING POLYPEPTIDE AGGREGATION - A method of determining aggregation rate data predicting an aggregation rate of a polypeptide defined by an amino acid sequence, the method comprising determining a hydrophobicity value, a charge value, and at least one shape propensity value for said sequence; identifying one or more aggregation-influencing patterns within said sequence; determining a pattern value for the sequence responsive to said identifying; and determining said aggregation rate data by determining a weighted combination of said hydrophobicity value, said charge value, said at least one shape propensity value, said pattern value and at least one factor extrinsic to said amino acid sequence.10-14-2010
20110178271STERILIZATION METHOD - The present invention relates to a method for sterilization of different materials, especially sensitive material, such as chromatographic media with sensitive ligands. The method for sterilization of a chromatographic separation medium comprises exposing the separation medium to pressurized steam at a temperature of between about 121° C. and about 135° C.07-21-2011
20110152501Activatable Imaging Probes - The invention relates to activatable imaging probes that include a chromophore attachment moiety and a plurality of chromophores, such as near-infrared chromophores, chemically linked to the chromophore attachment moiety so that upon activation of the imaging probe by interaction with a target molecule the optical properties of the plurality of chromophores are altered. The probe optionally includes protective chains or chromophore spacers, or both. Also disclosed are methods of using the imaging probes for in vivo and in vitro optical imaging.06-23-2011
20110178272ISOLATED BITTER TASTE RECEPTOR POLYPEPTIDES - The claimed invention relates to the discovery of a specific human taste receptor in the T2R taste receptor family, hT2R61 that responds to particular bitter compounds The present invention further relates to the use of this receptor in assays for identifying ligands that modulate the activation of this taste receptor. These compounds may be used as additives and/or removed from foods, beverages and medicinals in order to modify (block) T2R-associated bitter taste. A preferred embodiment is the use of the identified compounds as additives in foods, beverages and medicinals for blocking bitter taste.07-21-2011
20080242841METHODS OF MODULATING COLD SENSORY PERCEPTION - The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.10-02-2008
20080242840NOVEL INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH - This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the polypeptides of this invention can be used in fusion proteins, wherein the fusion proteins also comprise cell targeting or cytotoxic moieties. Also provided is the receptor to which these polypeptides bind.10-02-2008
20120065371Recombinant proteins from filoviruses and their use - Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.03-15-2012
20080255340ANGIOGENIN COMPLEXES (ANGex) AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.10-16-2008
20080255339Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities - The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by examples of chimeric proteins including recombinant chimeric proteins between a gonadoptropin releasing hormone (GnRH) and an apoptosis-inducing moiety, such as a pro-apoptotic member of Bcl-2 family, such as Bik, Bax and Bak, or caspases, such as caspase-3. The chimeric proteins specifically target cells expressing a GnRH-binding site, such as adenocarcinoma cells, and induce cell-specific apoptosis.10-16-2008
20120302732CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.11-29-2012
20110021751Plasmid Vector - To provide a plasmid vector having high productivity which can be used for large scale production of an industrially valuable and useful protein, and a transformant using the plasmid vector. A plasmid vector having DNA which encodes a plasmid replication protein in which one or more amino acid residues that are selected from (a) position 48, (b) position 262, (c) position 149 and (d) position 198 in the amino acid sequence represented by SEQ ID NO: 2 are substituted with (a) Ala, Gly, Thr, Arg, Glu, Asn or Gln, (b) Gly, Ser, Thr, Cys or Val, (c) Asn, and (d) Glu, respectively.01-27-2011
20110087006DNA Sequence Encoding a Retinoic Acid Regulated Protein - The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.04-14-2011
20110263823ENHANCED CAPACITY AND PURIFICATION OF PROTEIN BY MIXED MODE CHROMATOGRAPHY IN THE PRESENCE OF AQUEOUS-SOLUBLE NONIONIC ORGANIC POLYMERS - This invention relates to the use of mixed mode chromatography for purification of a protein from a mixture containing other materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies or other proteins suitable for in vivo applications.10-27-2011
20110028690NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate 02-03-2011
20110137012CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM - Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided.06-09-2011
20110124843METHOD FOR EFFICIENTLY AMPLIFYING ABNORMAL PRION PROTEIN DERIVED FROM BSE - A method for efficiently amplifying abnormal prion protein (PrP05-26-2011
20100168388STABILIZED P53 PEPTIDES AND USES THEREOF - Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.07-01-2010
20100168386FUSION PROTEIN CARRYING NEUROTROPHIN ACROSS THE BLOOD-BRAIN BARRIER, ENCODING GENE AND USES THEREOF - Provided are fusion proteins which comprise a first region having at least 75% homology with the amino acid sequence of neurotrophin, and a second region, located at the C-terminal of the first region, having at least 75% homology with the amino acid sequence of protein transduction domain (PTD). Also provided is encoding gene and usage thereof. The fusion protein can translocate through cell membrane or even the blood-brain barrier (BBB). The fusion protein can be used to treat various central nervous system degenerative diseases and peripheral neuropathy.07-01-2010
20100168387Chimeric CrylE Delta Endotoxin and Methods of Controlling Insects - The present invention relates to a chimeric δ endotoxin protein Cry 1E of SEQ ID No. 1 with extraordinarily high insecticidal property and a chimera gene of SEQ ID No. 2 encoding the said chimeric protein, and also a method of treating insect infested plants using said chimera protein.07-01-2010
20110178273METHOD FOR HIGH THROUGHPUT PEPTIDE/PROTEIN ASSAY GENERATION AND ASSAYS GENERATED THEREWITH - The invention relates to a method for the determination of an MRM or SRM assay for a protein of interest, a peptide of interest, or a group of proteins/peptides of interest or a whole proteome. It essentially includes the following steps: (1) a list of proteins of interest is selected and for each member at least one or a list of candidate proteotypic peptides is derived (2) this at least one peptide is synthesized/generated essentially without subsequent purification; (3) this at least one unpurified peptide is analyzed by selected reaction monitoring (SRM) preferably coupled to liquid chromatography (LC-SRM) or analogous techniques; (4) validation and/or optimisation of the corresponding assay of the at least one peptide with determination of the SRM coordinates for a peptide/protein of interest and/or of a regulator of interest is achieved. A protein sample of interest is enzymatically digested and can then be analyzed in SRM mode or time-constrained SRM mode, using elution times to trigger acquisition of the set of selected SRM traces, thus drastically increasing the throughput. The analysis allows to detect and quantify the set of peptides/proteins of interest. The method additionally relates to a tagging strategy to achieve absolute quantification of the peptides/proteins of interest at low-budget and high-throughput.07-21-2011
20090176969CLONING GENES FROM STREPTOMYCES CYANEOGRISEUS SUBSP. NONCYANOGENUS FOR BIOSYNTHESIS OF ANTIBIOTICS AND METHODS OF USE - The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant 07-09-2009
20110263820ANTIBODIES AND PROCESSES FOR PREPARING THE SAME - Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.10-27-2011
20100022752IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system (01-28-2010
20100016552Novel hemopoietic receptor protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.01-21-2010
20100036094Polypeptide Markers for the Diagnosis of Alzheimer's Disease - A method for the diagnosis of Alzheimer's disease, comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein the polypeptide marker is selected from markers 1 to 50 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 51 to 279 (amplitude markers)02-11-2010
20110028688CRYSTAL STRUCTURE OF OX40L AND OX40L COMPLEXED WITH OX40 RECEPTOR - The present disclosure provides crystals of and structural coordinates of mOX40L, hOX40L, hOX40 receptor and complexes thereof. The crystals and crystal structures are useful, for example, in the design and synthesis of modulators of mOX40L, hOX40L, and/or hOX40 receptor.02-03-2011
20110021750Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer.01-27-2011
20100160608PROTEIN STABILIZER - An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer.06-24-2010
20090209730METHOD FOR GENE TRANSFER INTO TARGET CELLS WITH RETROVIRUS - A polypeptide represented by SEQ. ID No. 13 and a gene encoding the polypeptide.08-20-2009
20100168390MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE - The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.07-01-2010
20110306751Independently Inducible System of Gene Expression - The present invention is directed to the improved methods for the temporal induction of proteins using the condensed single protein production (cSPP) system.12-15-2011
20100130725METHODS FOR CHARACTERIZING MOLECULES - Drug discovery is a complex undertaking facing many challenges, not the least of which is a high attrition rate as many promising candidates prove ineffective or toxic in the clinic owing to a poor understanding of the diseases, and thus the biological systems, they target. Therefore, it is broadly agreed that to increase the productivity of drug discovery one needs a far deeper understanding of the molecular mechanisms of diseases, taking into account the full biological context of the drug target and moving beyond individual genes and proteins. The present methods rely on the use of label-free cellular assays, particularly the DMR index, to systematically display the mode of actions, the toxicity, and the target(s) and pathway(s) of any molecules.05-27-2010
20090247733Novel Bone Mineralization Proteins, DNA, Vectors, Expression Systems - The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine. Finally, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention.10-01-2009
20100016553Internalization - A target internalized within a cell (and a binding member that specifically binds thereto) can be identified in an efficient manner by segregating (or substantially segregating) genetic material encoding the binding member from genetic material encoding a binding member that binds to a target that is not internalized. This can be achieved by employing a display library of binding members having a genotype/phenotype linkage via a non-fusion protein format, whereby genetic material encoding non-in-ternalized targets can be segregated (or substantially segregated) without lysing the cells. Internalized genetic material subsequently can be isolated and amplified.01-21-2010
20120041176UCP4 - The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.02-16-2012
20120041175NOVEL AUTOGRAPHY REGULATORS ATG14L AND RUBICON - The present invention provides for up- and down-regulation of cellular autophagy, e.g., for treating cancer or neurological disease. The invention results, in part, from discovery of two novel proteins, ATG14L (previously called “BISC”) and Rubicon (previously called “BIRC”), which bind to a Class III phophatidylinositol 3′-kinase (PI3K)/Vps34-Beclin 1 autophagic complex. ATG14L and Rubicon each regulate autophagic activity in an opposing manner. ATG14L and Rubicon can be used, for example, to increase/decrease autophagic activity, to increase/decrease PI3K/Vps34 kinase activity, and in so doing, treat diseases and disorders, such as cancer, neurodegenerative disease, stroke, metabolic disease, and age-related disease. ATG14L can increase autophagic activity and PI3K/Vps34 kinase activity; and Rubicon can decrease autophagic activity and PI3K/Vps34 kinase activity.02-16-2012
20120065373DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND NUCLEOTIDE SEQUENCE - The present invention relates to a dengue vaccine, a pharmaceutical composition including the same, and a nucleotide sequence. The dengue vaccine includes N and C termini-deleted nonstructural protein ΔNC NS1 with a peptide fragment from amino acids 36 to 270, which is derived from dengue virus nonstructural protein 1 (DV NS1) with deletions of N-terminal region from amino acids 1 to 35 and C-terminal region from amino acids 271 to 352. The dengue vaccine of the present invention is depleted of cross-reactivity with endothelial cells and platelets, and can shorten the bleeding time.03-15-2012
20090286956DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.11-19-2009
20120046446p16 MEDIATED REGULATION OF NMDA RECEPTORS - Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor.02-23-2012
20120004395Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia - The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.01-05-2012
20090088556FUSION ANTIGEN USED AS VACCINE AND METHOD OF MAKING THEM - Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a 04-02-2009
20120010386RECOMBINANT MELUSIN FUSION PROTEIN AS PHARMACOLOGICAL AGENT IN THE TREATMENT OF HEART PATHOLOGIES AND COMPOSITIONS THEREOF - A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity to SEQ ID No.:1 and having the function of native melusin protein or a human melusin portion derived from SEQ ID No.:1 or homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity of the melusin portion derived from SEQ ID No.:1 and having the function of native melusin protein and ii) a cell penetrating polypeptide.01-12-2012
20120010385SPLICE VARIANTS OF HUMAN G-PROTEIN COUPLED RECEPTOR HGPRBMY29 (HGPRMBY29SV2) - The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.01-12-2012
20110166323CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB1870 is a protein in 07-07-2011
20110166324IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.07-07-2011
20090018312IGF-1 RECEPTOR INTERACTING PROTEINS - The invention comprises a nucleic acid molecule with the sequence SEQ ID NO:5 and the complementary sequence, and its use in diagnosis and therapy. This nucleic acid molecule (IIP-10) is a gene which encodes an IGF-1 receptor binding polypeptide.01-15-2009
20120022232CELLS FOR INCREASED PROTEIN EXPRESSION COMPRISING ONE OR MORE RELEASE FACTORS AND METHODS OF USE - The invention provides recombinant cells or recombinant restrictive cells for overexpressing one or more proteins comprising one or more release factors. The invention also provides methods for producing a recombinant protein comprising culturing the cells of the present invention under conditions such that one or more proteins are overexpressed, and then isolating the expressed recombinant protein, In certain embodiments of the present invention, the gene encoding the protein is codon optimized.01-26-2012
20120059151Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X03-08-2012
20090192293ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR - The present invention provides antibodies that specifically bind to P2X07-30-2009
20120059150METHODS FOR THE PRODUCTION OF APOLIPOPROTEINS IN TRANSGENIC PLANTS - Methods for the production of an apolipoprotein in plants are described. In one embodiment, the present invention provides a method for the expression of apolipoprotein in plants comprising: 03-08-2012
20120065374DENDRITIC CELL CO-STIMULATORY MOLECULES - A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.03-15-2012
20100324267NOVEL TRAF FAMILY PROTEINS - In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases.12-23-2010
20120309939Production of Therapeutic Proteins in Photosynthetic Organisms - The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFNβ), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.12-06-2012
20120071631Isolation and Characterization of Novel Green Fluorescent Proteins from Copepods - The isolation and characterization of two protein isoforms collected green fluorescent copepods is described herein. The new 03-22-2012
20120071630Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and Their Use as Vaccines - The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.03-22-2012
20120071629APPOPTOSIN AND USES THEREOF FOR TREATING NEURODEGENERATIVE DISEASE AND CANCER - Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer.03-22-2012
20110092674Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X04-21-2011
20100184954MONOMERIC RED FLUORESCENT PROTEINS - Disclosed are sequences encoding monomeric variants of DsRed fluorescent proteins and methods of use.07-22-2010
20110065898Immunosuppressant Target Proteins - The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.03-17-2011
20120123093NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from 05-17-2012
20120316320PROCESS OF MANAGED ECOSYSTEM FERMENTATION - The presently disclosed subject matter relates to Managed Ecosystem Fermentation (MEF) which is a continuous microbial process utilizing a managed ecosystem approach employing dozens to thousands of species of microorganisms, occurring in a controlled artificial environment and consuming organic materials without benefit of sterilization. The process of utilizing this fermentation for the consumption of organic materials on a continuous basis is within the scope of this disclosed subject matter. The process of separating chemicals as industrial chemicals from this fermentation on a continuous basis is within the scope of this disclosed subject matter. The process of separating biomass useful as high protein animal feed or fertilizer from this fermentation on a continuous (or semi-continuous) basis is within the scope of this disclosed subject matter.12-13-2012
20120123095PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.05-17-2012
20120123094GREENER METHOD FOR THE PRODUCTION OF COPOLYMER 1 - The present invention provides a greener method for the production of polyamino acid random copolymers containing alanine, glutamic acid, lysine and tyrosine. In particular, the present invention provides a greener method for the production of Copolymer 1 or a pharmaceutically acceptable salt thereof via a synthetic route that only requires a single deprotection step.05-17-2012
20120123092HUMAN A2A ADENOSINE RECEPTOR CRYSTALS AND USES THEREOF - The invention provides the structure of human A2A adenosine receptor protein bound to an antagonist. Methods of using one or more binding sites and other features of this G-protein coupled receptor to develop new therapeutics are also disclosed.05-17-2012
20090131637Vanilloid receptor - The isolated nucleic acid encoding human vanilloid receptor, said receptor, it's preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. The receptor is involved in detection of noxious stimuli in mammalian organisms.05-21-2009
20120316319ARYLETHYNYLXANTHENE DYES - Disclosed are 9-arylethynylxanthenes which possess useful fluorescent properties, and can be used as fluorescent dyes, and labels.12-13-2012
20100204450Preparation Method for a Protein With New Function Through Simultaneous Incorporation of Functional Elements - Disclosed is a method for preparing a protein having a new function. The method comprises (A) a functional element-designing step of designing functional elements required for a new function desired to impart to an existing protein scaffold; (B) a functional element-inserting step of simultaneously inserting at least two gene fragments corresponding to the designed functional elements into a protein scaffold gene; and (C) a mutant screening and improving step of screening a mutant having a new function from a library of mutants inserted with the mutant genes, and improving and optimizing the function of the screened mutant using a directed evolution technique. The method for preparing can be widely used for the development of therapeutic proteins and the creation of industrial enzymes in the fields of bioengineering and biotechnology.08-12-2010
20120136137Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.05-31-2012
20100152422Compostion for Preventing and Treating Acetaminophen Inducing Liver Injury Comprising the Protein Extract from Porphyra Yezoensis - The present invention relates to a composition for preventing and treating acetaminophen induced liver injury comprising the protein extracts from 06-17-2010
20100048868Polypeptides Having Binding Affinity for Her2 - A polypeptide is provided, which has a binding affinity for HER2 and which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, as well as expression vector and host cell for expressing the nucleic acid, are also provided. Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing HER2. Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to HER2.02-25-2010
20100048870IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system (02-25-2010
20100048869AGENT COMPRISING G-CSF FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY - Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.02-25-2010
20100298540Crystal Structure of a MarR Family Polypeptide - The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in 11-25-2010
20100298539NOVEL POLYPEPTIDES AND USE THEREOF - The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of 11-25-2010
20100273987Soybean Cultivar 89146110 - A soybean cultivar designated 89146110 is disclosed. The invention relates to the seeds of soybean cultivar 89146110, to the plants of soybean 89146110, to plant parts of soybean cultivar 89146110 and to methods for producing a soybean plant produced by crossing soybean cultivar 89146110 with itself or with another soybean variety. The invention also relates to methods for producing a soybean plant containing in its genetic material one or more transgenes and to the transgenic soybean plants and plant parts produced by those methods. This invention also relates to soybean cultivars or breeding cultivars and plant parts derived from soybean variety 89146110, to methods for producing other soybean cultivars, lines or plant parts derived from soybean cultivar 89146110 and to the soybean plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid soybean seeds, plants and plant parts produced by crossing the cultivar 89146110 with another soybean cultivar.10-28-2010
20100273986POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.10-28-2010
20100273985POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.10-28-2010
20120220755ORGANIC CATION TRANSPORTER POLYPEPTIDES - Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.08-30-2012
20120316321METHODS FOR IDENTIFYING MARKERS FOR EARLY-STAGE HUMAN CANCER, CANCER PROGRESSION AND RECURRENCE - A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.12-13-2012
20120253013Early Growth Transcription Factors and Their Therapeutic Use - The present invention comprises a nucleotide which encodes a protein, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 1 (Egr3 DNA binding domain), for use in therapy.10-04-2012
20120226021Co-Crystallization of ERR-alpha with a Ligand that Forms a Reversible Covalent Bond - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.09-06-2012
20120226020HYBRID AND CHIMERIC POLYPEPTIDES THAT REGULATE ACTIVATION OF COMPLEMENT - A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units.09-06-2012
20120259093EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.10-11-2012
20120190824METHOD FOR HIGHLY SENSITIVE DETECTION OF PROTEIN-PROTEIN INTERACTION - The present invention intends to provide an assay system using split luciferase that has a remarkably high detection sensitivity. In an embodiment, binding of mutually binding first and second proteins is detected by preparing a first fusion protein comprising the first protein fused with a peptide having the amino acid sequence of amino acid SEQ ID NO: 1 and a second fusion protein comprising the second protein fused with a peptide having an amino acid sequence selected from the group consisting of amino acid SEQ ID NOS: 2 to 6, and allowing the first fusion protein to bind with the second fusion protein to form a complex, and detecting luminescence emitted from the complex.07-26-2012
20120190823ARTIFICIAL ENTROPIC BRISTLE DOMAIN SEQUENCES AND THEIR USE IN RECOMBINANT PROTEIN PRODUCTION - Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production.07-26-2012
20120232251GLUCOSE SENSOR - The invention relates to a glucose binding protein comprising amino acid mutations relative to the wild type sequence at the following positions: (i) H 152, (ii) A213; and (iii) L238 wherein the mutation at position H 152 is H152C. The invention further relates to such a glucose binding protein comprising the mutations H152C, A213R and L238S, in particular when linked to an environmentally sensitive dye such as badan.09-13-2012
20110046352DISEASE-RESISTANT PLANTS AND METHOD OF CONSTRUCTING THE SAME - The present invention provides transgenic, disease-resistant plants which have been transformed with an expression cassette including a constitutive gene expression promoter; and a gene, under the control of the promoter, encoding a harpin. The transformed cells in the transgenic plant effect the constitutive expression of the harpin in an amount effective for inducing a defense reaction. The harpin is a protein consisting of an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 2, and possesses a hypersensitive-response-inducing activity. The present invention also provides methods for producing the transgenic plants, expression cassettes, recombinant vectors and genes encoding harpins.02-24-2011
20110046351MUTANT PROTEINS AND METHODS FOR SELECTING THEM - A method for selecting a membrane protein with increased stability, the method comprising: a) providing one or more mutants of a parent membrane protein in a membrane-containing composition, wherein the one or more mutants are exposed to an amount of a membrane destabilising agent which is effective to destabilise the parent membrane protein in-situ, b) determining whether the or each mutant membrane protein has increased stability with respect to its structure and/or a biological activity compared to the stability of the parent membrane protein with respect to its structure and/or the same biological activity, and c) selecting the one or more mutants which have increased stability compared to the stability of the parent membrane protein.02-24-2011
20110046350LENGTH-ADJUSTABLE NANOSCALE TETHER FOR BINDING TARGETS TO SUBSTRATES - Embodiments of the present invention are directed to reusable, length-adjustable nanoscale tethers that can be incorporated into a variety of different sensors and other electrical, electro-mechanical, electro-optical-mechanical, and optical-mechanical devices. An optionally reusable, length-adjustable nanoscale tether that represents one embodiment of the present invention comprises a binding-structure component, having a substrate-anchor subcomponent and a binding-adapter binding domain, and a binding adaptor that binds to the binding-adapter binding domain and that has a target-binding subcomponent that binds to a target molecule, target particle, or other target entity. The binding-adapter binding domain can be positioned at different distances from the substrate anchor within the binding-structure component so that the distance between a bound target and a sensor substrate can be precisely controlled.02-24-2011
20120271035T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.10-25-2012
20120271036Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein - The present invention relates to large-scale production of ElonginB, ElonginC, Vif, and Cullin5. The present invention provides an assay for screening any agent that inhibits the ability of Vif to bind with Cul5. The invention provides an agent identified by the screening methods and methods of treatment using the identified agent.10-25-2012
20120322979Method of producing recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo - The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.12-20-2012
20110237777FUSION PROTEIN CONTAINING A SINGLE-STRANDED DNA BINDING PROTEIN AND METHODS FOR EXPRESSION AND PURIFICATION OF THE SAME - The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein. The present invention also provides a fusion protein comprising a single-stranded DNA binding protein and an interest protein or polypeptide fused directly or indirectly with the COOH-terminus or NH09-29-2011
20100234568Identification of peptide tags for the production of insoluble peptides by sequence scanning - A method is provided to identify short peptide tags, referred to here as inclusion body tags (IBTs), useful for the generation of insoluble fusion peptides. A library of genetic constructs were prepared encoding fusion peptides comprising an inclusion body tag of 10-50 contiguous amino acids from a full-length insoluble protein operably linked to a peptide of interest. The library was designed to include a sufficient number of overlapping inclusion body tags to ensure that the entire length of the full-length insoluble protein was represented. Host cells transformed and expressing the genetic constructs were evaluated for inclusion body formation.09-16-2010
20120277408HIGH-PURITY PRODUCTION OF MULTI-SUBUNIT PROTEINS SUCH AS ANTIBODIES IN TRANSFORMED MICROBES SUCH AS PICHIA PASTORIS - Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as 11-01-2012
20120329991AGENT FOR PREVENTING MUSCLE ATROPHY - A muscle atrophy-preventing agent includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, a branched-chain amino acid content of 20% or more, and an antigenicity equal to or less than 1/100,000th of that of β-lactoglobulin. The muscle atrophy-preventing agent exhibits an excellent muscle atrophy-preventing effect.12-27-2012
20120329990B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.12-27-2012
20110282031A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES - This invention relates to a diagnostic probe comprising a compound of formula (I):11-17-2011
20110319595FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypectides for the protection of mammals from the effects of apoptsis is described.12-29-2011
20120289683Purified Kunitz Trypsin Inhibitor Proteins Isolated from a Soy Processing Stream - A novel Kunitz-trypsin Inhibitor (KTI) isoform recovered from a processing stream and that has a total KTI protein concentration of at least about 95 wt. % is disclosed, as well as a process for recovering and isolating the purified KTI isoform from a processing stream.11-15-2012
20130012687INDUCIBLE SELF-CLEAVING PROTEASE TAG AND METHOD OF PURIFYING RECOMBINANT PROTEINS USING THE SAME - A method of purifying a protein is disclosed which entails: a) fusing a site-specific affinity-tagged cysteine protease domain to a target protein to form a tagged fusion protein; b) activating the site-specific cysteine protease domain of the tagged fusion protein by subjecting the site-specific affinity-tagged cysteine protease domain to an inducer, which induces autoprocessing at a cleavage site; thereby releasing untagged target protein; and c) isolating the untagged target protein.01-10-2013
20100174049Reversed mammalian protein-protein interaction trap - The invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The invention also relates to a method of screening compounds that disrupt compound-compound binding using the recombinant receptor.07-08-2010
20100130724MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.05-27-2010
20110160434FIBROMYALGIA TEST METHOD - A method for diagnosing or testing for fibromyalgia with a specific peptide in the blood as an indicator, as well as a method for effectively evaluating or assessing a fibromyalgia drug with the peptide as an indicator. A method for diagnosing or testing for fibromyalgia or for evaluating or assessing a fibromyalgia drug, by subjecting a patient's serum to peptide analysis using as an indicator (biomarker) a peptide that demonstrates a specific expression amount in the blood of a fibromyalgia patient.06-30-2011
20080234468Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.09-25-2008
20080227956Novel morphogenic protein compositions of matter - Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.09-18-2008
20110263821PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient.10-27-2011
20080221305Polynucleotides encoding novel adiponectin receptor variants - The present invention provides novel polynucleotides encoding human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.09-11-2008
20100010196COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF ENDOGENOUS GENES - The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by nontargeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. The invention also is directed to isolated genes, gene products, nucleic acid molecules, to compositions comprising such genes, gene products and nucleic acid molecules, and to vectors and host cells comprising such genes and nucleic acid molecules, that may be used in a variety of therapeutic and diagnostic applications. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.01-14-2010
20110269941METHOD OF LOADING A CRYSTALLIZATION DEVICE - The present invention pertains to a method for loading a crystallization device and for manufacturing a crystallization device comprising multiple receptacles with a pre-defined amount of at least one matrix-forming compound capable of forming a crystallization matrix for a membrane protein, said method comprising the following steps: a) Modifying the state of aggregation of said at least one matrix-forming compound to a fluidic state which allows dispensing said at least one matrix-forming compound, and b) dispensing a defined amount of said at least one matrix-forming compound into at least one receptacle of the crystallization device, wherein said dispensed matrix-forming compound solidifies within said receptacle. Thereby, pre-filled crystallization devices are obtained which can be used as consumables in particular in automated crystallization processes. Also provided are protein crystallization methods using respectively prepared crystallization devices.11-03-2011
20130096278THIOSULFONATE COMPOUND, REVERSIBLE CATIONIZATION AGENT FOR PROTEIN AND/OR PEPTIDE, AND METHOD FOR SOLUBILIZATION - The object of the present invention is to provide a novel thiosulfonate compound, a reversible cationization agent for protein and/or peptide, which can reversibly cationize a wider range of proteins and peptides with high stability of quality and accuracy and which are useful for a high degree of purification and recovery, as well as, a method for solubilization for protein and/or peptide using the agent.04-18-2013
20100280224MARKER SEQUENCES FOR MULTIPLE SCLEROSIS AND USE THEREOF - The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening of potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for multiple sclerosis, in particular a protein biochip and the use thereof.11-04-2010
20080200650Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use - The present invention provides isolated polypeptides isolatable from a 08-21-2008
20080200649Method - A method for optimised refolding of a protein which method comprises selecting for the protein at least three control factors which affect refolding of the protein and at least three levels for each control factor, making a Taguchi matrix of the control factors and levels, conducting experiments as required by the matrix, and refolding the protein in a process using the control factors at levels determined by the outcomes of the matrix experiments.08-21-2008
20110224406INTERLEUKIN-9 RECEPTOR MUTANTS - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.09-15-2011
20100286372Pregnane X Receptor Compositions, Crystals and Uses Thereof - The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.11-11-2010
20100286371Methods of Activating Clostridial Toxins - The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.11-11-2010
20100286370Novel fluorescent protein molecules - The present invention relates to novel fluorescent proteins and to methods of making these proteins and the uses thereof.11-11-2010
20100286369METHODS FOR GENERATING POLYNUCLEOTIDES HAVING DESIRED CHARACTERISTICS BY ITERATIVE SELECTION AND RECOMBINATION - A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.11-11-2010
20130150554CELL CULTURE OF GROWTH FACTOR-FREE ADAPTED CELLS - The present invention provides improved cell culture systems that allow optimum production of recombinant proteins. Among other things, the present invention provides methods of cell culture including a step of cultivating cells adapted to growth factor-free medium in a cell culture system that provides at least one growth factor.06-13-2013
20100298541Protein Scaffolds - The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.11-25-2010
20100317833METHOD FOR THE PRODUCTION OF DRY FREE-FLOWING HYDROPHOBIN PREPARATIONS - Method for the production of dry, free-flowing, stable hydrophobin preparations by spraying and drying aqueous hydrophobin solutions, if appropriate comprising additives in a spray device.12-16-2010
20120283413CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB1870 is a protein in Neisseria meningitidis. Three families of NMB1870 are known. To increase the ability of a NMB1870 protein to elicit antibodies that are cross-reactive between the families, NMB1870 is engineered. Sequences can be substituted from one NMB1870 family into the corresponding position in another family. Proteins of NMB1870 sequences from different families can be joined to each other.11-08-2012
20120283412ORPHAN NUCLEAR RECEPTOR - The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.11-08-2012
20130158235SELECTIVE MANUFACTURE OF RECOMBINANT NEUROTOXIN POLYPEPTIDES - The present invention pertains to recombinant neurotoxin polypeptides and the manufacture thereof. Specifically, it relates to a polynucleotide encoding a neurotoxin polypeptide comprising a light chain, a linker and a heavy chain, wherein the linker is a modified linker comprising an heterologous amino acid sequence which confers at least one physicochemical property to the polypeptide which allows for separation of partially processed and/or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides, said heterologous amino acid sequence being flanked N- and C-terminally by a protease recognition and cleavage site Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the polynucleotide and methods for the manufacture of processed neurotoxin polypeptide.06-20-2013
20130190477COMPLEMENT RECEPTOR 2 (CR2) TARGETING GROUPS - Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.07-25-2013
20120029169METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS - Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.02-02-2012
20130197192Method and Composition for Crystallizing G Protein-Coupled Receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.08-01-2013
20130203961Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen - This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo.08-08-2013
20120095188ESTABLISHMENT OF INDUCED PLURIPOTENT STEM CELL USING CELL-PERMEABLE REPROGRAMMING TRANSCRIPTION FACTOR FOR CUSTOMIZED STEM CELL THERAPY - The present invention relates to a reprogramming transcription factor recombinant protein in which a macromolecule transduction domain (MTD) is fused to a reprogramming transcription factor to obtain cell permeability. The present invention also relates to a polynucleotide for coding said reprogramming transcription factor recombinant protein and to an expression vector of said cell-permeable reprogramming transcription factor recombinant protein. Treating a somatic cell with the cell-permeable reprogramming transcription factor recombinant protein induces the reprogramming of the stem cell-specific gene of the somatic cell, and thus can be effectively used in the establishment of an induced pluripotent stem cell (iPS cell) having characteristics similar to those of an embryonic stem cell in terms of morphology and genetics.04-19-2012

Patent applications in class PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES

Patent applications in all subclasses PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES